n addition, samples can be taken from virtually any
ulation so that the genotypes and phenotypes of the
This can be especially advantageous if researchers want
pecific patient populations.
ll® product lines, CDI provides industrialized quantities
terminal tissue cells to pharmaceutical companies and
turn utilize them in drug discovery programs to screen
fects before they enter animal testing and eventually
.
lar Dynamics can produce over two billion iPS cells
cility,” says Robert Palay, CEO of Cellular Dynamics
ke regular adult human cells and reverse their
to turn them into stem cells, which in turn can grow
in the human body.
ompanies will spend about $100 billion-plus each year on
ost of that money, about two-thirds, is spent on human
adds. “Current cells used in drug discovery and drug
e from animals, such as dog, rat, or rhesus monkey;
ers; so they’re not really predictive of human response.”
onizes Our Approach to Health page 347
September 2012
